Asmanex/Foradil combo development
Executive Summary
Schering-Plough and Novartis will develop Asmanex/Foradil combination product to treat asthma and chronic obstructive pulmonary disorder, the companies announced April 10. Schering's pending NDA for Asmanex (mometasone) was submitted Nov. 30, 1998. In November 2002, Schering acquired U.S. marketing rights to Novartis' Foradil (formoterol) (1"The Pink Sheet" Nov. 4, 2002, p. 22)...
You may also be interested in...
Schering-Plough Puffs Up Asthma Line With Foradil From Novartis
Schering-Plough is plugging a hole in its asthma product line by in-licensing Novartis' Foradil
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.